Clinical trial
Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection
NCT00300807 · XTL Biopharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00300807 |
|---|---|
| Title | Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection |
| Official title | A Phase I, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Safety and Virologic Effects of Ascending Single (and Multiple) Doses of XTL6865 in Patients With Chronic Hepatitis C Virus Infection |
| Lead sponsor | XTL Biopharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | XTL 6865 |
| Enrollment | 36 |
| Start date | Oct 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Mar 9, 2006 |
| Last update posted | Mar 7, 2007 |
| Countries | Israel, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: